About Michael Guzman
Form D filings for RS BioTherapeutics from 2022 to 2024 list Michael Guzman as executive officer.
Michael Guzman first appears on SEC filings in 2022.
Experience
This experience comes from SEC filings. The years are when the filings name Michael Guzman in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Michael Guzman works with at each company, as listed on that company's latest Form D.
RS BioTherapeutics Inc. · Form D, Oct 9, 2024
HH
H. Hart
Executive officer
CR
Curtis Rhine
Chief Financial Officer
JM
Justin Molignoni
Executive officer and director
DF
David Freas
Director